BNR Burning Rock Biotech Ltd Annual reports only
Services-Medical Laboratories · Nasdaq · SEC CIK 1792267
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · CNY |
|---|---|---|
| Income statement | ||
| Revenue | $77.16M | 515.82M |
| Cost of revenue | $19.54M | 153.42M |
| Gross profit | $57.62M | 362.40M |
| R&D expense | $23.81M | 232.29M |
| SG&A expense | $18.03M | 261.64M |
| Operating income | -$7.84M | -357.56M |
| Pretax income | -$7.69M | -340.74M |
| Income tax | $223,000 | 5.88M |
| Net income | -$7.92M | -346.63M |
| EBITDA | -$4.73M | -305.36M |
| EPS (diluted) | — | — |
| Banking | ||
| Net interest income | -$4,000 | 0 |
| Balance sheet | ||
| Cash & equivalents | $68.41M | 519.85M |
| Receivables | $24.25M | 152.01M |
| Inventory | $6.95M | 53.76M |
| Current assets | $105.62M | 776.62M |
| PP&E, net | $4.45M | 47.15M |
| Intangibles | $41,000 | 421,000 |
| Total assets | $117.31M | 885.30M |
| Current liabilities | $35.32M | 266.30M |
| Long-term debt | $243,000 | 0 |
| Total debt | $243,000 | 0 |
| Total liabilities | $40.77M | 304.48M |
| Shareholders' equity | $76.54M | 580.83M |
| Net debt | -$68.17M | -519.85M |
| Cash flow statement | ||
| Operating cash flow | -$4.07M | -92.26M |
| Capital expenditure | $751,000 | 5.42M |
| Free cash flow | -$4.82M | -97.68M |
| Investing cash flow | -$628,000 | -4.41M |
| Financing cash flow | $272,000 | -72,000 |
| Depreciation & amortization | $3.11M | 52.20M |
| Stock-based compensation | $1.98M | 155.62M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.